주식/증권
📉 부정적
Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low
요약
The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.